EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.
Issue link: https://digital.eyeworld.org/i/78710
AS C RS The official publication of the American Society of Cataract & Refractive Surgery May 2012 Publisher Donald R. Long dlong@eyeworld.org Editorial Editor Stephanie Graham stephanie@eyeworld.org Assistant Editor Stacy Majewicz smajewicz@eyeworld.org EyeWorld Staff Writers Faith Hayden faith@eyeworld.org Jena Passut jena@eyeworld.org Production Graphic Designer Julio Guerrero jguerrero@eyeworld.org Production Manager Cathy Stern cstern@eyeworld.org 703-383-5702 Production Assistant Karen Salerni ksalerni@eyeworld.org Contributing Editors Vanessa Caceres Lakeland, Florida Michelle Dalton Reading, Pennsylvania Rich Daly Arlington, Virginia Volume 17 • No. 5 PUBLISHING STAFF Enette Ngoei Singapore Matt Young Malaysia Senior Contributing Editor Maxine Lipner Nyack, New York Advertising Sales ASCRSMedia 4000 Legato Road Suite 700 Fairfax, VA 22033 703-591-2220 fax: 703-591-0614 eyeworld@eyeworld.org www.eyeworld.org Advertising Sales Managers Jeff Brownstein jbrownstein@eyeworld.org 703-788-5745 Paul Zelin pzelin@eyeworld.org 703-383-5729 Classified Sales Cathy Stern cstern@eyeworld.org 703-383-5702 EyeWorld Special Projects and Events Jessica Donohoe jdonohoe@eyeworld.org 703-591-2220 Mitchell P. Weikert, M.D., cataract editorial board member P hysicians are in a constant struggle to balance the quality of care we provide to our patients with the economic bur- den that this care places upon them. We are confronted with this challenge on a daily basis when it comes to the periopera- tive pharmacologic therapy that we use in cataract surgery. In addition to anesthetics, the three classes of pharmaceuticals that are routinely employed include antibiotics, steroids, and non- steroidal anti-inflammatory drugs (NSAIDs). Not that long ago, we were able to provide some of these medications at no cost to our patients. However, with changes in PhRMA guidelines and decreased sampling of medications related to off-label use, these practices have been drastically reduced. And while several truly outstanding medications have recently become commercially available, we have also seen a steady increase in the economic burden borne by our patients. As such, it is incumbent upon us to critically evaluate our therapeutic decisions to optimize cost/benefit ratios and to communicate with our patients about the risks and benefits associ- ated with alternate therapeutic options. This month's issue of EyeWorld addresses these complicated issues by fo- cusing on the perioperative pharmacology used in conjunction with cataract surgery. The first topic of discussion is the use of NSAIDs for the prevention of cystoid macular edema (CME). The evidence is clear that the risk of CME is lower when topical NSAIDs are used in combination with steroids versus steroids alone, whether patients are "high risk" or not. While surveys, in- cluding this issue's Monthly Pulse, have shown that approximately 80% of surgeons use NSAIDs, the pre- and post-op dosing regimens can be highly variable. Some may question their necessity given the low incidence of clini- cal CME. Whether you believe this or not, the idea certainly raises some worthy questions: Are they worth the added expense? Does the cost (time and money) of treating CME justify the expense of trying to prevent it? What alternate therapies are available? What are the risks of these alternate therapies? Our first cover story answers these questions and more. The next article addresses the use of anesthesia in cataract surgery. In ASCRS Publisher: EYEWORLD (ISSN 1089-0084) is published monthly by ASCRS Ophthalmic Services Corp., 4000 Legato Road, Suite 700, Fairfax, VA 22033-4003; telephone: 703-591-2220; fax: 703-591-0614. Printed in the U.S. Editorial Offices: EYEWORLD News Service, 4000 Legato Road, Suite 700, Fairfax, VA 22033-4003; toll-free: 800-451-1339, 703-591-2220; fax: 703-591-0614; email: eyeworld@eyeworld.org. Advertising Offices: ASCRSMedia, 4000 Legato Road, Suite 700, Fairfax, VA 22033-4003; toll-free: 800-451-1339, 703-591-2220; fax: 703-591-0614; email: eyeworld@eyeworld.org. Copyright 2012, ASCRS Ophthalmic Services Corp., 4000 Legato Road, Suite 700, Fairfax, VA 22033-4003. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. Letters to the editor and other unsolicited material are assumed intended for publication and are subject to editorial review and acceptance. Subscriptions: Requests should be addressed to the publisher. Annual subscription prices: Individual: 1 year, $120; 2 years, $220; 3 years, $320. Institutional: 1 year, $250; 2 years, $330; 3 years, $425. Foreign: 1 year, $240, 2 years $470, 3 years, $700. Back copies: Subject to availability. Contact the publisher. Cost per copy is $15; $30 foreign. All orders for individual or back copies must be accompanied by payment. Requests to reprint, use, or republish: Requests to reprint or use material published herein should be made in writing only to Cathy Stern, EYEWORLD, 4000 Legato Road, Suite 700, Fairfax, VA 22033-4003; toll-free: 800-451-1339, 703-591-2220; fax: 703-591-0614; email: eyeworld@eyeworld.org. EYEWORLD reprints: To order reprints of material published in EYEWORLD, contact Cathy Stern, EYEWORLD, 4000 Legato Road, Suite 700, Fairfax, VA 22033-4003; toll-free: 800-451-1339, 703-591-2220; fax: 703-591-0614; email: cstern@eyeworld.org or your salesperson. Change of address: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses and label from recent issue. The publisher cannot accept responsibility for undelivered copies. POSTMASTER: Send change of address to EYEWORLD, 4000 Legato Road, Suite 700, Fairfax, VA 22033. Periodical postage paid at Fairfax, VA 22033 and at additional mailing offices. The ideas and opinions expressed in EYEWORLD do not necessarily reflect those of the editors, publisher, or its advertisers. general, it looks like topical anesthesia "rules the roost," with retro- or peribulbar blocks reserved for more difficult cases. Injection anesthesia continues to serve a vital role in training residents, but more and more pro- grams are transitioning their trainees to topical anesthesia at a fairly rapid pace. Upon closer observation, the choices of topical anesthetic regimens are almost as varied as the surgeons using them: gels versus drops, pre-op hold- ing versus the OR, benzodiazepines versus propofol versus narcotics. Whatever the method, the recommendation is to work closely with your anesthesia service to create a system that individualizes the treatment for each patient. Compare your preferred methods to those discussed inside. Even though no topical antibiotics are actually FDA-approved for infec- tion prophylaxis in cataract surgery, they are still the primary choice for most surgeons. In fact, 95% of the Monthly Pulse survey respondents use topical antibiotic drops alone or in combination with other routes of admin- istration. The choice of the most appropriate one should include considera- tion of coverage spectra, MIC levels, and resistance patterns. The use of intracameral antibiotics is definitely gaining traction following the recent ESCRS study. While many may question the original choice of cefuroxime, it's hard to argue with the clinical results. However, the question remains, "What is the preferred antibiotic choice and route to prevent post-op infec- tions?" This is especially important in light of the increasing prevalence of methicillin-resistant Staphylococcal species. Strategies for combatting antibiotic resistance are also addressed in this issue. We hope that you enjoy these articles and will find this information useful as you make your own decisions regarding medication use in cataract surgery. Mitchell P. Weikert, M.D., cataract editorial board member World view It's a balancing act: Drug therapy choices in 2012